Day One Biopharmaceuticals Inc DAWN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DAWN is a good fit for your portfolio.
News
-
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
-
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
-
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
-
Day One Biopharmaceuticals Shares Rally on FDA Priority Review
-
Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor
-
Apple, Circor, Palo Alto stocks climb, Epam, Mallinckrodt shares tumble and other stocks on the move
-
Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment
Trading Information
- Previous Close Price
- $16.48
- Day Range
- $16.20–17.46
- 52-Week Range
- $9.67–17.85
- Bid/Ask
- $14.33 / $17.50
- Market Cap
- $1.49 Bil
- Volume/Avg
- 47 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 155
- Website
- https://www.dayonebio.com
Comparables
Valuation
|
Metric
|
DAWN
|
BMEA
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.30 | 2.28 | 2.88 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
DAWN
BMEA
CELC
Financial Strength
|
Metric
|
DAWN
|
BMEA
|
CELC
|
|---|---|---|---|
Quick Ratio | 12.42 | 7.74 | 12.78 |
Current Ratio | 12.72 | 7.84 | 13.43 |
Interest Coverage | — | — | −12.43 |
Quick Ratio
DAWN
BMEA
CELC
Profitability
|
Metric
|
DAWN
|
BMEA
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −39.08% | −56.31% | −35.57% |
Return on Equity (Normalized) | −41.67% | −65.70% | −49.08% |
Return on Invested Capital (Normalized) | −41.60% | −67.02% | −39.21% |
Return on Assets
DAWN
BMEA
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qlhgqgwck | Ybr | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jhkckhhx | Wtsqvqs | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qzgfglxd | Rkwgm | $98.1 Bil | |
MRNA
| Moderna Inc | Wkqqzpb | Knsn | $42.2 Bil | |
ARGX
| argenx SE ADR | Bwcmszml | Srcfw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rzqmvtch | Bzc | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kzvfvynq | Cwxjhwm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wdbymfz | Sfxyrjt | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tgxqwmbgs | Zprgy | $12.5 Bil | |
INCY
| Incyte Corp | Msggjzqmd | Bbrpqb | $11.7 Bil |